FDA began collecting the fees Oct. 1. The fees will help ensure FDA will “continue to have access to the resources necessary to approve of safe, effective and affordable generic medicines,” according to the statement.
“Timely access to effective and affordable medications is critical for American hospitals and patients. HSCA applauds both government and industry for each doing their part to help protect uninterrupted patient access to important treatments,” said HSCA President Curtis Rooney, in the statement. “Group purchasing organizations are engines of healthcare cost savings and the purchasing partners to America’s 5,000-plus hospitals. GPOs are acutely aware of the important role of generic prescriptions drugs in helping to control healthcare spending.”
Related Articles on Supply Chain:
Global Ophthalmology Devices Market Projected to Reach $18B in 2018
DePuy Mitek Launches New Rotator Cuff Anchor
Covidien Unveils Cordless Ultrasonic Dissection Device and Stapling System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
